| pubmed-article:19884008 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19884008 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:19884008 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:19884008 | lifeskim:mentions | umls-concept:C0684224 | lld:lifeskim |
| pubmed-article:19884008 | lifeskim:mentions | umls-concept:C0278488 | lld:lifeskim |
| pubmed-article:19884008 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:19884008 | pubmed:dateCreated | 2010-2-17 | lld:pubmed |
| pubmed-article:19884008 | pubmed:abstractText | Metronomic chemotherapy has shown efficacy in patients with metastatic breast cancer. Pegylated liposomal-doxorubicin (PLD) pharmacokinetic characteristics support the rationale for using the drug in a metronomic fashion, potentially able to combine anthracyclines efficacy to a low toxicity profile. | lld:pubmed |
| pubmed-article:19884008 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19884008 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19884008 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19884008 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19884008 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19884008 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19884008 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19884008 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19884008 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:19884008 | pubmed:issn | 1532-3080 | lld:pubmed |
| pubmed-article:19884008 | pubmed:author | pubmed-author:Di PietroAA | lld:pubmed |
| pubmed-article:19884008 | pubmed:author | pubmed-author:GoldhirschAA | lld:pubmed |
| pubmed-article:19884008 | pubmed:author | pubmed-author:AdamoliLL | lld:pubmed |
| pubmed-article:19884008 | pubmed:author | pubmed-author:NolèFF | lld:pubmed |
| pubmed-article:19884008 | pubmed:author | pubmed-author:MarenghiCC | lld:pubmed |
| pubmed-article:19884008 | pubmed:author | pubmed-author:RadiceDD | lld:pubmed |
| pubmed-article:19884008 | pubmed:author | pubmed-author:VerriEE | lld:pubmed |
| pubmed-article:19884008 | pubmed:author | pubmed-author:MunzoneEE | lld:pubmed |
| pubmed-article:19884008 | pubmed:author | pubmed-author:CuriglianoGG | lld:pubmed |
| pubmed-article:19884008 | pubmed:author | pubmed-author:MinchellaII | lld:pubmed |
| pubmed-article:19884008 | pubmed:author | pubmed-author:Cossu RoccaMM | lld:pubmed |
| pubmed-article:19884008 | pubmed:copyrightInfo | Copyright (c) 2009 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:19884008 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19884008 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:19884008 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19884008 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19884008 | pubmed:pagination | 33-7 | lld:pubmed |
| pubmed-article:19884008 | pubmed:meshHeading | pubmed-meshheading:19884008... | lld:pubmed |
| pubmed-article:19884008 | pubmed:meshHeading | pubmed-meshheading:19884008... | lld:pubmed |
| pubmed-article:19884008 | pubmed:meshHeading | pubmed-meshheading:19884008... | lld:pubmed |
| pubmed-article:19884008 | pubmed:meshHeading | pubmed-meshheading:19884008... | lld:pubmed |
| pubmed-article:19884008 | pubmed:meshHeading | pubmed-meshheading:19884008... | lld:pubmed |
| pubmed-article:19884008 | pubmed:meshHeading | pubmed-meshheading:19884008... | lld:pubmed |
| pubmed-article:19884008 | pubmed:meshHeading | pubmed-meshheading:19884008... | lld:pubmed |
| pubmed-article:19884008 | pubmed:meshHeading | pubmed-meshheading:19884008... | lld:pubmed |
| pubmed-article:19884008 | pubmed:meshHeading | pubmed-meshheading:19884008... | lld:pubmed |
| pubmed-article:19884008 | pubmed:meshHeading | pubmed-meshheading:19884008... | lld:pubmed |
| pubmed-article:19884008 | pubmed:meshHeading | pubmed-meshheading:19884008... | lld:pubmed |
| pubmed-article:19884008 | pubmed:meshHeading | pubmed-meshheading:19884008... | lld:pubmed |
| pubmed-article:19884008 | pubmed:meshHeading | pubmed-meshheading:19884008... | lld:pubmed |
| pubmed-article:19884008 | pubmed:meshHeading | pubmed-meshheading:19884008... | lld:pubmed |
| pubmed-article:19884008 | pubmed:meshHeading | pubmed-meshheading:19884008... | lld:pubmed |
| pubmed-article:19884008 | pubmed:meshHeading | pubmed-meshheading:19884008... | lld:pubmed |
| pubmed-article:19884008 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:19884008 | pubmed:articleTitle | Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report. | lld:pubmed |
| pubmed-article:19884008 | pubmed:affiliation | Division of Medical Oncology, European Institute of Oncology, via Ripamonti 435, Milan, Italy. elisabetta.munzone@ieo.it | lld:pubmed |
| pubmed-article:19884008 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19884008 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
